Preparation of extended metaphase chromosomes from human cultured cells using a topoisomerase II inhibitor, ICRF-193

被引：2
|
作者：
Kohda, A [1 ]
Taguchi, H [1 ]
Okumura, K [1 ]
机构：
[1] Mie Univ, Fac Bioresources, Mol & Cellular Biol Lab, Tsu, Mie 5148507, Japan
来源：
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY | 2001年 / 65卷 / 05期
关键词：
chromosome preparations; fluorescence in situ hybridization; topoisomerase II inhibitor; HL60; HepG2;
D O I：
10.1271/bbb.65.1248
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Effects of ICRF-193, a topoisomerase II inhibitor, on metaphase chromosome preparations were examined. A short-time exposure of this drug to human HL60 cells in a suspension culture before harvest resulted in obtaining more extended metaphase chromosomes, The length, of chromosome 6 identified by fluorescence in situ hybridization was twice as long with this drug treatment. Together with effectiveness for adherent HepG2 cells, these results suggest that treatments with ICRF-193 provide a simple and reliable method for chromosome preparations from extended cultured metaphase cells.
引用
收藏
页码：1248 / 1251
页数：4
相关论文
共 31 条
  • [1] High yield of endoreduplication induced by ICRF-193:: a topoisomerase II catalytic inhibitor
    Pastor, N
    Flores, MJ
    Domínguez, I
    Mateos, S
    Cortés, F
    MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2002, 516 (1-2) : 113 - 120
  • [2] Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange
    Hamatake, M
    Andoh, T
    Ishida, R
    ANTI-CANCER DRUGS, 1997, 8 (06) : 637 - 642
  • [3] ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells
    Iwai, M
    Hara, A
    Andoh, T
    Ishida, R
    FEBS LETTERS, 1997, 406 (03) : 267 - 270
  • [4] Effects of an inhibitor of topoisomerase II, ICRF-193 on the formation of ultraviolet-induced chromosomal aberrations
    Ikushima, T
    Shima, Y
    Ishii, Y
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1998, 404 (1-2) : 35 - 38
  • [5] The topoisomerase II catalytic inhibitor ICRF-193 preferentially targets telomeres that are capped by TRF2
    Chen, Lianxiang
    Zhu, Xiaowei
    Zou, Yaru
    Xing, Jun
    Gilson, Eric
    Lu, Yiming
    Ye, Jing
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2015, 308 (05): : C372 - C377
  • [6] The SUMO pathway is required for selective degradation of DNA topoisomerase IIβ induced by a catalytic inhibitor ICRF-193
    Isik, S
    Sano, K
    Tsutsui, K
    Seki, M
    Enomoto, T
    Saitoh, H
    Tsutsui, K
    FEBS LETTERS, 2003, 546 (2-3): : 374 - 378
  • [7] Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIα
    Patel, S
    Jazrawi, E
    Creighton, AM
    Austin, CA
    Fisher, LM
    MOLECULAR PHARMACOLOGY, 2000, 58 (03) : 560 - 568
  • [8] Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells
    Beere, HM
    Chresta, CM
    Hickman, JA
    MOLECULAR PHARMACOLOGY, 1996, 49 (05) : 842 - 851
  • [9] Abnormal chromosome migration and chromosome aberrations in mouse oocytes during meiosis II in the presence of topoisomerase II inhibitor ICRF-193
    Tateno, H
    Kamiguchi, Y
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2002, 502 (1-2) : 1 - 9
  • [10] ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells
    Hossain, MS
    Akimitsu, N
    Takaki, T
    Hirai, H
    Sekimizu, K
    GENES TO CELLS, 2002, 7 (03) : 285 - 294
1234